Natco Pharma Share Price Gains 2.48% After Semaglutide Launch Announcement

Mumbai, March 20: Natco Pharma share price rose 2.48% to ₹961.35 as of 10:26 AM IST on Friday, compared with its previous close of ₹938.05, following a key product launch update.

The stock opened at ₹950.00 and pushed higher in early trade, touching ₹972.50 so far before trimming some gains.

Why Natco Pharma Share Price Moved

In a filing dated March 20, 2026, Natco Pharma announced the launch of generic Semaglutide injection in India.

The company said the product will be introduced in multi-dose vial format starting March 21, 2026, aligning with the patent expiry timeline. Approval from the Central Drugs Standard Control Organisation had already been secured in February 2026.

Natco pegged the starting monthly cost at ₹1,290 for select strengths, positioning the product significantly below prevailing market levels. In a therapy area like GLP-1, that matters.

Natco Pharma Stock Performance Snapshot

As of 10:26 AM IST on March 20, 2026, the stock was trading at ₹961.35, up 2.48% so far. It moved within a range of ₹948.20 to ₹972.50 so far during the session.

Market capitalisation was around ₹17,220 crore. The stock has seen a broad trading band over the past year, with a high of ₹1,059.00 and a low of ₹726.80, placing current levels somewhere in the upper half of that range.

What This Means for Investors

Lower pricing could widen access and drive volumes, especially in a cost-sensitive market like India. That said, real traction will depend on prescriptions, doctor confidence, and how quickly distribution scales up.

Broader Market and Sectoral Context

Pharma companies have been actively tracking patent expires in high-value therapies, and GLP-1 is one of the most closely watched segments right now.

In contrast to complex innovation cycles, generics tied to patent cliffs often deliver quicker commercial visibility. Markets tend to respond early, especially when pricing advantage is clear.

About the Company

Natco Pharma Limited operates across generics, specialty pharmaceuticals, and active pharmaceutical ingredients, with a strong footprint in oncology.

The company has built a niche by targeting limited-competition products and leveraging its regulatory and manufacturing capabilities across key markets.

Conclusion

Natco Pharma share price gains on March 20, 2026, reflect a positive but measured response to its Semaglutide launch. The opportunity is visible, but execution will determine how much of that potential translates into earnings.

Source;

• https://www.nseindia.com/get-quote/equity/NATCOPHARM/Natco-Pharma-Limited
• https://nsearchives.nseindia.com/corporate/NATCOPHARM_20032026093010_PressReleasee_20032026.pdf